NovoCure/$NVCR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About NovoCure

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Ticker

$NVCR
Primary listing

Industry

Health Care Equipment and Supplies

Headquarters

Baar, Switzerland

Employees

1,488

ISIN

JE00BYSS4X48

NovoCure Metrics

BasicAdvanced
$1.8B
-
-$1.51
0.65
-

What the Analysts think about NovoCure

Analyst ratings (Buy, Hold, Sell) for NovoCure stock.

Bulls say / Bears say

NovoCure's Tumor Treating Fields (TTFields) therapy demonstrated a significant delay in brain metastases progression in non-small cell lung cancer patients, potentially enhancing treatment efficacy and patient outcomes. (proactiveinvestors.com)
The company received CE Mark approval for Optune Lua® for treating metastatic non-small cell lung cancer, expanding its market reach in Europe. (stocktitan.net)
Analysts have recently upgraded NovoCure's stock, with Piper Sandler raising the price target from $28.00 to $42.00, indicating confidence in the company's growth prospects. (marketbeat.com)
NovoCure reported a Q4 loss of $0.61 per share, missing revenue estimates and indicating financial challenges. (nasdaq.com)
The company announced layoffs affecting 13% of its workforce as part of a restructuring effort, which may signal internal challenges. (investorplace.com)
A securities class action lawsuit has been filed against NovoCure, alleging misleading statements regarding clinical trial results, potentially impacting investor confidence. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

NovoCure Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NovoCure Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVCR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs